Treatments for rare diseases are hard to create and expensive to deliver, but there is new hope for editing the software of ...

Series B financing in XyloCor Therapeutics to develop Novel Gene Therapy in Cardiovascular Disease Proceeds of financing will ...

Seven-year-old Archie Ennis has been diagnosed with Duchenne muscular dystrophy, a genetic condition that causes muscle ...

Moderate drinking was once thought to have benefits for the heart, but better research methods have thrown cold water on that ...

Enliven Therapeutics' ELVN-001 shows promising results for CML patients. Click here to read what makes ELVN stock a ...

This genetic disorder is caused by a tiny mutation in the LMNA gene, leading to ... therapy and occupational therapy can help ...

XyloCor Therapeutics, Inc., ("XyloCor"), a clinical stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today announced the completion of a $67.5 million Series ...

Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A. Recent estimates suggest a prevalence of 1 in 34,810 to as high as 1 in 8,664 ...

RyCarma Therapeutics, Inc., formerly known as ARMGO Pharma (the "Company" or "RyCarma"), a clinical-stage biotech company developing first-in-class small molecule therapeutics for cardiovascular and ...

Over €420k has been raised for a seriously ill young boy named Archie following an emotional plea from his mother after a ...

While some things improved compared to 2023, there are still many areas that need attention, even as we enter 2025.